Payment overview · 2025
General Payments
$1,263.57
68 reported records · 22 companies
Healthcare provider profile · identity verified
Peter Duros, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OREM, UT · NPI 1669498119
Verified facts
What the public records show
CMS Open Payments records show Peter Duros, MD received $1,263.57 in general payments during 2025 across 68 reported records.
ABBVIE INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rexulti, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $310.42 | 24.6% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $92.58 | 7.3% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $85.34 | 6.8% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $80.82 | 6.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.27 | 6.3% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $74.49 | 5.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $66.78 | 5.3% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $63.09 | 5.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $62.16 | 4.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.57 | 3.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.40 | 3.7% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $45.60 | 3.6% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.26 | 3.1% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $30.13 | 2.4% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $26.42 | 2.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.98 | 1.5% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.64 | 1.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.69 | 1.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.66 | 1.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.97 | 1.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $13.83 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.47 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,263.57 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $164.31 | 8 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $146.11 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $117.70 | 6 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $92.58 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $85.34 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $80.82 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $74.49 | 4 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $69.60 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $63.09 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $62.16 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $55.99 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.57 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $47.04 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.26 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $31.71 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.35 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.42 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $30.13 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $29.77 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $29.77 | 2 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $28.09 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| EDARBYCLOR Normalized: edarbyclor |
Drug | Azurity Pharmaceuticals, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $13.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 123 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 105 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
26 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
67 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
105 | 25 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 828 | 230 |
| Omeprazole | Omeprazole | 660 | 206 |
| Atorvastatin Calcium | Atorvastatin Calcium | 603 | 190 |
| Zolpidem Tartrate | Zolpidem Tartrate | 429 | 78 |
| Lisinopril | Lisinopril | 395 | 113 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 373 | 61 |
| Alprazolam | Alprazolam | 361 | 55 |
| Losartan Potassium | Losartan Potassium | 353 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 352 | 112 |
| Simvastatin | Simvastatin | 335 | 95 |
| Gabapentin | Gabapentin | 332 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 285 | 95 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 267 | 41 |
| Tramadol Hcl | Tramadol Hcl | 253 | 52 |
| Potassium Chloride | Potassium Chloride | 217 | 69 |
| Celecoxib | Celecoxib | 193 | 70 |
| Trazodone Hcl | Trazodone Hcl | 191 | 60 |
| Metformin Hcl Er | Metformin Hcl | 190 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 188 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 182 | 63 |
| Metformin Hcl | Metformin Hcl | 179 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 168 | 49 |
| Glimepiride | Glimepiride | 167 | 45 |
| Furosemide | Furosemide | 165 | 62 |
| Lorazepam | Lorazepam | 156 | 29 |
| Allopurinol | Allopurinol | 146 | 41 |
| Finasteride | Finasteride | 140 | 41 |
| Meloxicam | Meloxicam | 134 | 40 |
| Bupropion Xl | Bupropion Hcl | 127 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 47 |
| Eliquis | Apixaban | 123 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 122 | 20 |
| Sertraline Hcl | Sertraline Hcl | 122 | 35 |
| Clonazepam | Clonazepam | 121 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 113 | 32 |
| Pregabalin | Pregabalin | 112 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 109 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 32 |
| Ozempic | Semaglutide | 105 | 25 |
| Temazepam | Temazepam | 105 | 20 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 102 | 18 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 102 | 84 |
| Pioglitazone Hcl | Pioglitazone Hcl | 100 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 32 |
| Diazepam | Diazepam | 98 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 24 |
| Carvedilol | Carvedilol | 90 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 17 |
| Promethazine Hcl | Promethazine Hcl | 86 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 82 | 29 |
| Donepezil Hcl | Donepezil Hcl | 82 | 26 |
| Eszopiclone | Eszopiclone | 79 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 78 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 27 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 75 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 74 | 20 |
| Montelukast Sodium | Montelukast Sodium | 73 | 21 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 72 | 19 |
| Glipizide Er | Glipizide | 71 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 17 |
| Azithromycin | Azithromycin | 69 | 59 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 25 |
| Trulicity | Dulaglutide | 67 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 20 |
| Cefuroxime | Cefuroxime Axetil | 64 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 64 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 62 | suppressed |
| Lamotrigine | Lamotrigine | 60 | 14 |
| Propranolol Hcl | Propranolol Hcl | 59 | 16 |
| Chlorthalidone | Chlorthalidone | 58 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 20 |
| Methocarbamol | Methocarbamol | 55 | 11 |
| Famotidine | Famotidine | 54 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 53 | 17 |
| Carisoprodol | Carisoprodol | 51 | suppressed |
| Spironolactone | Spironolactone | 50 | 16 |
| Synthroid | Levothyroxine Sodium | 49 | 13 |
| Xarelto | Rivaroxaban | 49 | 19 |
| Ondansetron Odt | Ondansetron | 48 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 46 | 12 |
| Benazepril Hcl | Benazepril Hcl | 45 | 13 |
| Ibuprofen | Ibuprofen | 45 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 45 | 18 |
| Buspirone Hcl | Buspirone Hcl | 44 | 14 |
| Valacyclovir | Valacyclovir Hcl | 44 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 38 |
| Alendronate Sodium | Alendronate Sodium | 42 | 14 |
| Estradiol | Estradiol | 41 | 15 |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 40 | suppressed |
| Cephalexin | Cephalexin | 39 | 27 |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Sotalol | Sotalol Hcl | 38 | 13 |
| Clonidine Hcl | Clonidine Hcl | 37 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 12 |
| Prednisone | Prednisone | 36 | 27 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 33 | 11 |
| Valsartan | Valsartan | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | 13 |
| Fluconazole | Fluconazole | 31 | 18 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Olanzapine | Olanzapine | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Myrbetriq | Mirabegron | 26 | 12 |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 16 |
| Ramipril | Ramipril | 25 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 24 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Topiramate | Topiramate | 23 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Methimazole | Methimazole | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Triazolam | Triazolam | 21 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Zaleplon | Zaleplon | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 16 | suppressed |
| Alogliptin | Alogliptin Benzoate | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Jardiance | Empagliflozin | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Budesonide Dr | Budesonide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Trimethoprim | Trimethoprim | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,263.57 · 68 records | ABBVIE INC. | ABRYSVO, AREXVY, CAPLYTA, CAPVAXIVE, COMIRNATY, EDARBYCLOR, ELIQUIS, EVENITY, INGREZZA, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, SYNTHROID, Senza, Sunosi, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, WaveWriter Alpha Prime 16, Wegovy, YUPELRI, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error